A phase II clinical trial (NCT03745716) evaluating APR-246 in combination with azacitidine in patients with TP53-mutant myelodysplastic syndromes (MDS) and AML reported a complete remission (CR) rate of 50% and a median overall survival (OS) of 10.8 months. This evidence concerns the gene TP53 and myelodysplastic syndrome.